Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Effects and Safety of Crovalimab for Adults and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying atypical Hemolytic Uremic Syndrome (aHUS), a rare disease that affects the blood and kidneys. The study will evaluate a treatment called Crovalimab, which is administered as a solution for injection or infusion. The purpose of the study is to assess how effective and safe Crovalimab is for patients who have not previously received treatment that inhibits a part of the immune system known as the complement system.

Participants in the study will receive Crovalimab through injections under the skin or infusions into a vein. The study will monitor various health indicators, such as kidney function and blood health, to determine the treatment's impact. The study will also track any side effects or reactions to the treatment, including changes in fatigue levels and any adverse events that may occur.

The trial aims to understand how well Crovalimab works in controlling the symptoms of aHUS and improving patients' overall health. The study will gather information over a period of time to see how patients respond to the treatment and whether it helps maintain control over the disease. This research is important for developing new treatment options for people living with aHUS.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    The study begins with an initial assessment to confirm eligibility. This includes ensuring vaccination against Neisseria meningitidis within the last three years, adequate liver function, and for women of childbearing potential, a commitment to abstinence or contraception.

    For patients new to treatment, the onset of initial symptoms must have occurred within 28 days before the first dose of crovalimab.

  2. Step 2

    Treatment initiation

    The treatment involves the administration of crovalimab, which is a solution for injection or infusion. It is administered either subcutaneously or intravenously, depending on the specific requirements of the study.

    The objective is to evaluate the effect of crovalimab in patients who have not previously received complement inhibitor treatment.

  3. Step 3

    Monitoring and evaluation

    Throughout the study, various health parameters are monitored. This includes the requirement for dialysis, changes in kidney function, blood parameters, and fatigue levels in adults.

    The study also tracks the incidence and severity of any adverse events, including reactions at the injection site, infusion-related reactions, and infections.

  4. Step 4

    Response assessment

    The primary goal is to determine the proportion of patients achieving a complete response to treatment. This involves monitoring platelet counts, lactate dehydrogenase (LDH) levels, and serum creatinine levels.

    Secondary assessments include changes in chronic kidney disease stage, vital signs, and the presence of anti-drug antibodies.

  5. Step 5

    Study completion

    The study is estimated to conclude by December 7, 2029. During this period, the effectiveness and safety of crovalimab will be thoroughly evaluated.

    The study aims to provide comprehensive data on the long-term management of atypical hemolytic uremic syndrome (aHUS) with crovalimab.

Who can join the trial?

8 criteria

  • The patient must have been vaccinated against Neisseria meningitidis (a type of bacteria) within the last 3 years before starting the study treatment, following local guidelines or standard care for patients with complement deficiency (a condition where part of the immune system is not working properly).
  • The patient must have adequate liver function, with AST and ALT (liver enzymes) levels no more than 3 times the upper limit of normal at the time of screening. There should be no clinical signs or known evidence of cirrhosis (severe liver damage).
  • Female patients who can have children must agree to either not have heterosexual intercourse or use contraception.
  • For patients who have not received complement inhibitor treatment before, the first signs of TMA (a condition affecting blood and kidneys) must have appeared within 28 days before the first dose of the study drug, crovalimab.
  • For patients switching from other treatments, there must be clinical evidence of response to either eculizumab or ravulizumab, shown by a platelet count at or above the lower limit of normal, LDH (an enzyme) at or below the upper limit of normal, and stable or improving kidney function, measured at two separate times at least 4 weeks apart before starting crovalimab treatment.
  • For patients with a known C5 polymorphism (a genetic variation), such as Arg885, they may be eligible for a specific group in the study.
  • The study is open to both male and female patients.
  • The study includes patients from vulnerable populations.

Who cannot join the trial?

6 criteria

  • Patients who have previously received treatment with a **complement inhibitor**. A complement inhibitor is a type of medication that affects a part of the immune system called the complement system.
  • Patients who are not within the specified age range for the study. The study includes specific age groups, so patients must fall within these age categories to participate.
  • Patients who have any medical condition that the study doctors believe would make it unsafe for them to participate. This could include other serious health problems.
  • Patients who are unable to follow the study procedures or attend the required study visits. This means they must be able to understand and agree to the study requirements.
  • Patients who are pregnant or breastfeeding. This is to ensure the safety of both the mother and the baby.
  • Patients who are participating in another clinical trial at the same time. This is to avoid any interference with the study results.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Crovalimab is a medication being studied for its effects on patients with atypical Hemolytic Uremic Syndrome (aHUS). This condition is a rare disease that affects the blood and kidneys. Crovalimab works by inhibiting a part of the immune system called the complement system, which is thought to play a role in the development of aHUS. The study aims to evaluate how effective and safe Crovalimab is for patients who have not previously received treatment with complement inhibitors.

What is already known about the treatment

Crovalimab – Crovalimab is administered through intravenous infusion, allowing the medication to be delivered directly into the bloodstream. It is currently being studied in clinical trials, particularly for its effectiveness and safety in treating atypical Hemolytic Uremic Syndrome (aHUS). The main therapeutic indication for Crovalimab is to manage aHUS, a rare disease that affects the blood and kidneys. At the molecular level, Crovalimab works by inhibiting the complement system, a part of the immune system that, when overactive, can lead to the symptoms of aHUS. It is classified pharmacologically as a complement inhibitor, aiming to prevent the immune system from attacking the body's own cells.

Investigated diseases

Atypical Hemolytic Uremic Syndrome (aHUS) – Atypical Hemolytic Uremic Syndrome is a rare disease that affects the blood and blood vessels. It is characterized by the destruction of red blood cells, low platelet count, and kidney failure due to damage to the small blood vessels in the kidneys. The disease can lead to the formation of blood clots in small blood vessels, which can cause damage to various organs. aHUS is often triggered by an abnormal activation of the immune system, specifically the complement system, which is part of the body's defense against infections. The progression of the disease can vary, with some individuals experiencing sudden and severe symptoms, while others may have a more gradual onset. It is important to monitor kidney function and blood parameters in individuals with aHUS to manage the disease effectively.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-505089-27-00Protocol codeBO42353Estimated enrolment81 patientsSponsorF. Hoffmann-La Roche AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.